Dr. Corbeil received his bachelor of science degree, with a concentration in biochemistry, and a master of science, with a concentration in experimental medicine, from Universit Laval. He obtained his PhD from the University of New South Wales in Sydney, Australia , where he studied HIV-associated Kaposi’s sarcoma. Dr. Corbeil then moved to the University of California in San Diego for postdoctoral training in infectious diseases. He created the UCSD Center for AIDS Research Genomics core laboratory and achieved associate professor status, before moving back to Quebec City. Dr. Corbeil’s research at the Quebec City Genome Centre focuses on host pathogen relationships, specifically in AIDS, tuberculosis and, more recently, in Leishmaniasis, using genomic and bioinformatic tools. He also investigates virally associated cancers, molecular diagnostic methodologies, and is passionate about the metagenomics of marine microorganisms. Dr. Corbeil is a member of the Scientific Advisory Board of the CIHR Cancer Institute and of a number of biotechnology oriented companies.
Dr. Tony Hunter, a professor in the Molecular and Cell Biology Laboratory and director of the Salk Institute Cancer Center, studies how cells regulate their growth and division, and how mutations in genes that regulate growth lead to cancer. His lab has made significant contributions in the area of signal transduction, how signals that stimulate or rein in growth are routed within a cell. In 1979, his lab discovered that phosphate can be attached to tyrosine residues in proteins. This seminal discovery opened the door to the study of tyrosine kinases and their role in signal transduction, and in cell growth and development, as well as to their role in cancer and other human diseases. This knowledge already has resulted in a new approach to cancer treatment. His current efforts are aimed at elucidating how protein phosphorylation, ubiquitination, and SUMOylation events are used to regulate cell proliferation and growth control, and cell cycle checkpoint activation in response to DNA damage. His recent work has highlighted the importance of crosstalk and feedback loops in the PI-3 kinase-Akt-mTOR cell growth pathway, has elucidated mechanisms of activation of the ATM protein kinase in response to double strand DNA breaks, and has identified a role for the ERK MAP kinase pathway in the motility of early breast carcinoma cells.
Marc is the Director of Biotherapeutics, Genetics Institute of the Novartis Research Foundation, San Diego, CA. Antibodies are essential human proteins that are involved in the immune system’s ability to recognize and eliminate pathogens, and they can also be& therapeutic treatments for a number of human diseases. The goal of the GNF antibody program is to advance biotherapeutics into the Novartis drug discovery pipeline. Currently, we& are focused on the development of therapeutic antibodies, but our long-term plans include development of other types of biologics.
To the family of Bill Huse,
Please accept our sincere condolences for the loss of Bill.
Bill and Genlantis CEO, Tony Sorge, relationship goes back more than 30 years as friends and business associates. Bill was Vice President of Research and Development at Stratagene, Inc., a private biotechnology company in San Diego, from 1986 to 1989. He had a great sense of humor and was a wonderful leader. In short, Bill was an exceptional friend, colleague and board member who will be deeply missed by all who knew him.
Please know that we here at Genlantis collectively mourn the loss of Bill.
The employees at Genlantis